冠昊生物(300238.SZ):上半年淨利預增40%-60%
格隆匯7月9日丨冠昊生物(300238.SZ)公佈2021年半年度業績預吿,公司預計上半年歸屬於上市公司股東的淨利潤盈利3800萬元–4300萬元,比上年同期增長40%-60%。
隨着國內疫情得到有效控制,國內經濟復甦,公司把握市場機遇,以市場為導向,積極適應國家政策,調整經營及營銷策略,加強資源配置與協同。報吿期內,公司主要業務板塊銷量較上年同期均有所提升。
為保持和擴大公司的技術領先優勢,堅持科技創新,公司繼續加強研發項目的投入,報吿期內,研究費-費用化支出約1,900萬元(2020年同期研究費-費用化支出1,709.61萬元)。
報吿期內,公司預計非經常性損益對淨利潤的影響金額為876萬元(2020年同期非經常性損益對淨利潤的影響金額為733.82萬元)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.